RecruitingPhase 2NCT07226453

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

A Target Validation and Efficacy Study of Metformin in Patients With Recurrent or Progressive Posterior Fossa Group A (PFA) Ependymoma

Sponsor

University of California, San Francisco

Enrollment

30 participants

Start Date

May 5, 2026

Study Type

INTERVENTIONAL

Conditions

Posterior Fossa Ependymal Tumor

Summary

This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.

Eligibility

Min Age: 1 YearMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called MR spectroscopy (MRS), a procedure called Magnetic Resonance Imaging (MRI), and others for people with posterior fossa ependymal tumor. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 1 Year to 39 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin

Given orally (PO)

PROCEDUREPlanned Surgical Resection

Undergo planned surgery as part of regular care

PROCEDUREMagnetic Resonance Imaging (MRI)

Undergo MRI imaging

PROCEDURESpecimen Collection

Tumor Tissue, blood, and cerebral spinal fluid (CSF) may be collected for correlative analysis.

PROCEDUREMR spectroscopy (MRS)

Undergo MRS imaging

Locations(5)

University of California, San Francisco

San Francisco, California, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

St. Louis Children's Hospital, Washington University in St. Louis

St Louis, Missouri, United States

Duke University

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226453